264 related articles for article (PubMed ID: 21732248)
1. A comparative study of fragment screening methods on the p38α kinase: new methods, new insights.
Pollack SJ; Beyer KS; Lock C; Müller I; Sheppard D; Lipkin M; Hardick D; Blurton P; Leonard PM; Hubbard PA; Todd D; Richardson CM; Ahrens T; Baader M; Hafenbradl DO; Hilyard K; Bürli RW
J Comput Aided Mol Des; 2011 Jul; 25(7):677-87. PubMed ID: 21732248
[TBL] [Abstract][Full Text] [Related]
2. A combinatorial biophysical approach; FTSA and SPR for identifying small molecule ligands and PAINs.
Redhead M; Satchell R; Morkūnaitė V; Swift D; Petrauskas V; Golding E; Onions S; Matulis D; Unitt J
Anal Biochem; 2015 Jun; 479():63-73. PubMed ID: 25837771
[TBL] [Abstract][Full Text] [Related]
3. SPR-based fragment screening: advantages and applications.
Neumann T; Junker HD; Schmidt K; Sekul R
Curr Top Med Chem; 2007; 7(16):1630-42. PubMed ID: 17979772
[TBL] [Abstract][Full Text] [Related]
4. Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification.
Kobayashi M; Retra K; Figaroa F; Hollander JG; Ab E; Heetebrij RJ; Irth H; Siegal G
J Biomol Screen; 2010 Sep; 15(8):978-89. PubMed ID: 20817886
[TBL] [Abstract][Full Text] [Related]
5. Fragment-based discovery of focal adhesion kinase inhibitors.
Grädler U; Bomke J; Musil D; Dresing V; Lehmann M; Hölzemann G; Greiner H; Esdar C; Krier M; Heinrich T
Bioorg Med Chem Lett; 2013 Oct; 23(19):5401-9. PubMed ID: 23973211
[TBL] [Abstract][Full Text] [Related]
6. Fragment-based lead generation: identification of seed fragments by a highly efficient fragment screening technology.
Neumann L; Ritscher A; Müller G; Hafenbradl D
J Comput Aided Mol Des; 2009 Aug; 23(8):501-11. PubMed ID: 19533372
[TBL] [Abstract][Full Text] [Related]
7. Experiences in fragment-based lead discovery.
Hubbard RE; Murray JB
Methods Enzymol; 2011; 493():509-31. PubMed ID: 21371604
[TBL] [Abstract][Full Text] [Related]
8. From experimental design to validated hits a comprehensive walk-through of fragment lead identification using surface plasmon resonance.
Giannetti AM
Methods Enzymol; 2011; 493():169-218. PubMed ID: 21371592
[TBL] [Abstract][Full Text] [Related]
9. p38α MAPK and Type I Inhibitors: Binding Site Analysis and Use of Target Ensembles in Virtual Screening.
Astolfi A; Iraci N; Sabatini S; Barreca ML; Cecchetti V
Molecules; 2015 Aug; 20(9):15842-61. PubMed ID: 26334265
[TBL] [Abstract][Full Text] [Related]
10. [Progress in the fragment-based drug discovery].
Ren J; Li J; Shi F; Wang X; He JH; Xu YC; Zhang NX; Xiong B; Shen JK
Yao Xue Xue Bao; 2013 Jan; 48(1):14-24. PubMed ID: 23600136
[TBL] [Abstract][Full Text] [Related]
11. A combination of
Nagatoishi S; Yamaguchi S; Katoh E; Kajita K; Yokotagawa T; Kanai S; Furuya T; Tsumoto K
Bioorg Med Chem; 2018 May; 26(8):1929-1938. PubMed ID: 29510947
[No Abstract] [Full Text] [Related]
12. Fragment-based screening using surface plasmon resonance technology.
Perspicace S; Banner D; Benz J; Müller F; Schlatter D; Huber W
J Biomol Screen; 2009 Apr; 14(4):337-49. PubMed ID: 19403917
[TBL] [Abstract][Full Text] [Related]
13. High-throughput screening to identify inhibitors which stabilize inactive kinase conformations in p38alpha.
Simard JR; Grütter C; Pawar V; Aust B; Wolf A; Rabiller M; Wulfert S; Robubi A; Klüter S; Ottmann C; Rauh D
J Am Chem Soc; 2009 Dec; 131(51):18478-88. PubMed ID: 19950957
[TBL] [Abstract][Full Text] [Related]
14. Combining biophysical screening and X-ray crystallography for fragment-based drug discovery.
Hennig M; Ruf A; Huber W
Top Curr Chem; 2012; 317():115-43. PubMed ID: 21837555
[TBL] [Abstract][Full Text] [Related]
15. [Fragment screening using surface plasmon resonance optical biosensor technology].
Miura T
Yakugaku Zasshi; 2010 Mar; 130(3):341-8. PubMed ID: 20190519
[TBL] [Abstract][Full Text] [Related]
16. An Automated Microscale Thermophoresis Screening Approach for Fragment-Based Lead Discovery.
Linke P; Amaning K; Maschberger M; Vallee F; Steier V; Baaske P; Duhr S; Breitsprecher D; Rak A
J Biomol Screen; 2016 Apr; 21(4):414-21. PubMed ID: 26637553
[TBL] [Abstract][Full Text] [Related]
17. Label free fragment screening using surface plasmon resonance as a tool for fragment finding - analyzing parkin, a difficult CNS target.
Regnström K; Yan J; Nguyen L; Callaway K; Yang Y; Diep L; Xing W; Adhikari A; Beroza P; Hom RK; Riley B; Rudolph D; Jobling MF; Baker J; Johnston J; Konradi A; Bova MP; Artis DR
PLoS One; 2013; 8(7):e66879. PubMed ID: 23861750
[TBL] [Abstract][Full Text] [Related]
18. Enzyme fragment complementation binding assay for p38alpha mitogen-activated protein kinase to study the binding kinetics of enzyme inhibitors.
Zaman GJ; van der Lee MM; Kok JJ; Nelissen RL; Loomans EE
Assay Drug Dev Technol; 2006 Aug; 4(4):411-20. PubMed ID: 16945014
[TBL] [Abstract][Full Text] [Related]
19. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
[TBL] [Abstract][Full Text] [Related]
20. The discovery of novel protein kinase inhibitors by using fragment-based high-throughput x-ray crystallography.
Gill A; Cleasby A; Jhoti H
Chembiochem; 2005 Mar; 6(3):506-12. PubMed ID: 15696598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
